--- title: ROCOCO - Adaptive IMRT Versus IMPT in Head and Neck Cancer nct_id: NCT02908386 overall_status: WITHDRAWN sponsor: Maastricht Radiation Oncology study_type: OBSERVATIONAL primary_condition: Head and Neck Neoplasms countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02908386.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02908386" ct_last_update_post_date: 2016-09-21 last_seen_at: "2026-05-12T07:04:27.113Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # ROCOCO - Adaptive IMRT Versus IMPT in Head and Neck Cancer **Official Title:** In Silico Clinical Trial on Adaptive Radiotherapy in Oropharynx Cancer, Comparing Photon & Proton Therapy: A Multicentric ROCOCO Planning Study Based on a Reference Dataset. **NCT ID:** [NCT02908386](https://clinicaltrials.gov/study/NCT02908386) ## Key Facts - **Status:** WITHDRAWN - **Why Stopped:** At the moment no participants are enrolled untill a new agreement is made - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 0 - **Lead Sponsor:** Maastricht Radiation Oncology - **Collaborators:** University of Pennsylvania - **Conditions:** Head and Neck Neoplasms - **Start Date:** 2015-11 - **Completion Date:** 2016-11 - **CT.gov Last Update:** 2016-09-21 ## Brief Summary Given the lack of evidence for the benefit of particle therapy in relevant cases, he investigators proposed an in silico trial to investigate the dosimetric effect of contour changes for OAR as well as tumor during chemoradiation in H\&N patients. Photon and proton-therapy will be compared based on dosimetric data on 7 time points during treatment combined with plan robustness. In that way the investigators will be able to assess and compare the optimal timing for replanning for photon and proton therapy. A database of the University of Pennsylvania (Upenn) consists of 10 patients with head and neck tumors treated with chemo-radiation. Contrast-enhanced CT scans were acquired prior and during RT (T1-T7) ## Detailed Description Given that the cost of particle therapy (PT) is considerably higher than that of conventional radiotherapy (RT) with photons, it is necessary to establish whether these higher costs are worthwhile in light of the expected advantages. Thus, clear evidence of the situations in which PT outperforms conventional photon treatment is needed. ROCOCO (Radiation Oncology COllaborative Comparison) is commenced at MAASTRO in May 2007 to evaluate PT's cost-effectiveness . It is well known that during radiation treatment of head and neck cancer (HN), shrinkage and displacement of tumour and organs at risk (OARs, e.g. parotid glands), as well as weight loss may cause significant radiation dose changes to target volumes and organs at risk , , . These phenomena may cause the necessity to re-plan the treatment at a certain moment in time. In the last years many different treatment planning studies have been performed showing that the optimum moment for re-planning varies: after 20 Gy, 35 or 46 Gy. But what the actual effect of the deformation is on dose in actually treated patients has not been reported. The investigators propose an in silico trial to investigate the relevance of contour changes for OAR as well as tumor during chemo radiation in H\&N patients which will eventually lead to replanning. In that way the investigators will be able to assess and compare the optimal timing for replanning for photon and proton therapy. The investigators compare different treatments focusing on the effect of deformation on PTV coverage and normal tissue radiation exposure. A fixed tumor dose, using the same delineation of gross target volume (GTV), clinical target volume (CTV) is used. The planning target volume (PTV) will be determined by each treatment modality. For the initial plan the best possible dose distribution will be determined using the planning-CT (reference scan). For every time point (CT-scan) the reference treatment plan will be projected on the actual CT scan and the dose will be recalculated without changing the treatment parameters. This will be done using both photons and protons. All treatment uncertainties including robustness will be taken into account. Dose differences in the target volume (CTV-GTV and PTV) and the OAR, as a result of tumor shrinkage during treatment will be evaluated for each time point and each treatment modality. The objective of this study is to assess plan robustness and the optimal timing for replanning for photon and proton therapy. ## Eligibility - **Minimum age:** 19 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * patients with head and neck carcinoma who have been treated with radical intent 10 patients, all with a reference CT scan and CT scans at 7 time points during treatment. Exclusion Criteria: * patients with no head and neck cancer ``` ## Primary Outcomes - **Dose distribution** _(time frame: up to 26 weeks)_ — Dose values of seven time frames (T1-T7) are compared to the reference dose values on the planning CT for both photon and proton treatment plans. ## Secondary Outcomes - **Optimal timing for replanning** _(time frame: up to 26 weeks)_ ## Locations (1) - University of Pennsylvania, Philadelphia, Pennsylvania, United States ## Recent Field Changes (last 30 days) - `status.whyStopped` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.university of pennsylvania|philadelphia|pennsylvania|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02908386.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02908386* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*